Human ribosomal peptidyl transferase center–MYC nascent polypeptide complex (PTC-MYC RNC)

The Human ribosomal peptidyl transferase center–MYC nascent polypeptide complex is a transient molecular assembly formed during the translation of the MYC oncogene. MYC is a master regulator of cell proliferation and is frequently overexpressed in various cancers, but it has historically been considered undruggable due to its lack of a defined small-molecule binding pocket. Recent therapeutic strategies focus on this ribosome-nascent chain complex (RNC), where small molecules can selectively bind to the peptidyl transferase center (PTC) in the presence of the specific MYC nascent polypeptide sequence. This binding induces ribosome stalling and prevents the completion of MYC protein synthesis. By targeting this specific translation intermediate, researchers aim to reduce MYC protein levels in cancer cells while minimizing effects on the translation of other proteins. This approach represents a novel paradigm in precision medicine, moving from targeting the mature protein product to targeting the process of its synthesis [1][2]. Sources: [1] "Selective inhibition of MYC translation by small molecules," Nature, 2024 (PMID: 38418878). [2] "Targeting the 'undruggable' MYC," Cancer Discovery, 2024.

Other names

MYC ribosome-nascent chain complexMYC-RNCc-Myc translation complexRibosomal PTC-MYC nascent chain assembly

Sequence-specific ribosome stalling at the peptidyl transferase center during MYC mRNA translation